Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT03715582

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03715582
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03715582. Randomized; quadruple masking; primary purpose prevention. Start 2018-10-01 (actual); primary completion 2020-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes
Acronym
Trimeta
Condition
Diabetes Mellitus
Condition
Angina, Unstable
Intervention (Drug)
trimetazidine
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
University of Sao Paulo General Hospital (class: other)

Record details

Record id
cardio:ct-nct03715582
Content hash
dc6076db3e06fdb5d42e4c608afa4792f0b4a44ba93de6490f609d2df0543002